FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220756780> ?p ?o ?g. }

• W4220756780 endingPage "02" @default.
• W4220756780 startingPage "P3" @default.
• W4220756780 abstract "Abstract Background: Checkpoint blockade pembrolizumab has demonstrated great potential to improve pathologic outcome for HER2- breast cancer. The apparent diffusion coefficient (ADC) is a non-contrast MRI-derived biomarker that is sensitive to changes in tumor cellularity. Clinical trial ACRIN 6698, a sub-study of I-SPY 2, demonstrated that ADC can predict pathologic complete response (pCR). This study compares the utility of ADC for early prediction of pCR in patients with HER2- breast cancer randomized to pembrolizumab versus standard neoadjuvant chemotherapy (NACT) in I-SPY 2. Methods: A retrospective analysis of imaging and clinical data was performed on a cohort of 249 women diagnosed with high-risk, stage II/III breast cancer. All patients were randomized to the standard NACT (paclitaxel) or pembrolizumab plus paclitaxel for 12 weeks, followed by doxorubicin plus cyclophosphamide. MRI exams performed at pretreatment (T0) and 3 weeks after the treatment started (T1) were analyzed. Tumor ADC was calculated within manually delineated region-of-interests on diffusion-weighted MRI. The percent change of ADC from T0 to T1 was evaluated in the prediction of pCR after NACT. Statistical analysis included Wilcoxon rank sum test and the area under the ROC curve (AUC). A p-value &lt;0.05 was considered statistically significant. Results: A subcohort of 103 patients with analyzable diffusion-weighted MRI exams and known pCR (n=30)/non-pCR (n=73) outcome were included in this analysis. Among 103 patients, 62 had HR+/HER2- and 41 had triple negative breast cancer. Twenty-eight patients (17 HR+/HER2- and 11 triple negative) were randomized to receive pembrolizumab and 75 (45 HR+/HER2- and 30 triple negative) to standard NACT. Tumor ADC increased at 3 weeks in both standard and pembrolizumab cohorts with median ADC change of 11.5% (interquartile range [IQR]: 4.6, 16.2)% and 14.4% (IQR: 0.2, 19.9)%, respectively. In the pembrolizumab cohort, the difference in ADC change between non-pCR and pCR groups was estimated as -9.7% (95% confidence interval [CI]: -22.4, -0.9), with ADC increasing more in the pCR group. The AUC of predicting pCR in the pembrolizumab cohort was estimated as 0.73 (95%CI: 0.52, 0.93), while it was estimated as 0.63 (95% CI: 0.43, 0.83) in the standard NACT cohort. In comparison, the AUCs using functional tumor volume (FTV) to predict pCR were 0.61 (95%CI: 0.39, 0.83) and 0.66 (95% CI: 0.47, 0.85) in the corresponding cohorts (Table 1). The results suggest that ADC had higher association with pCR than FTV in the pembrolizumab cohort and FTV had higher association than ADC in the standard cohort. Conclusions: Tumor ADC, measured using diffusion-weighted MRI, demonstrates potential as a biomarker for assessing early response to immunotherapy in the neoadjuvant setting for high risk HER2- breast cancer. This study is limited by sample size. Future analysis with larger cohorts is warranted. Table 1.Association between MRI variables and pCRN (pCR rate)Difference between non-pCR and pCR groups (95% CI)AUC (95% CI)pDiffusion weighted MRI (percent change of ADC)Pembrolizumab28 (54%)-9.7 (-22.4, -0.9)0.73 (0.52, 0.93)0.041Standard75 (20%)-5.6 (-13.9, 2.1)0.63 (0.43, 0.83)0.13DCE-MRI (percent change of FTV)Pembrolizumab28 (54%)10.6 (-18.3, 43.9)0.61 (0.39, 0.83)0.34Standard74 (20%)25.3 (-0.6, 49)0.66 (0.47, 0.85)0.056 Citation Format: Wen Li, Nu N Le, Natsuko Onishi, David C Newitt, Jessica E Gibbs, Lisa J Wilmes, John Kornak, Savannah C Partridge, Barbara LeStage, Elissa R Price, Bonnie N Joe, I-SPY 2 TRIAL Imaging Working Group, I-SPY 2 TRIAL Consortium, Laura J Esserman, Nola M Hylton. Diffusion-weighted MRI for prediction of pathologic complete response in HER2- breast cancer treated with pembrolizumab plus neoadjuvant chemotherapy [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-03-02." @default.
• W4220756780 created "2022-04-03" @default.
• W4220756780 creator A5001969147 @default.
• W4220756780 creator A5010926549 @default.
• W4220756780 creator A5012847376 @default.
• W4220756780 creator A5015982056 @default.
• W4220756780 creator A5016580708 @default.
• W4220756780 creator A5023543805 @default.
• W4220756780 creator A5024284558 @default.
• W4220756780 creator A5027791567 @default.
• W4220756780 creator A5033270425 @default.
• W4220756780 creator A5034796205 @default.
• W4220756780 creator A5061131007 @default.
• W4220756780 creator A5072789687 @default.
• W4220756780 creator A5076174825 @default.
• W4220756780 date "2022-02-15" @default.
• W4220756780 modified "2023-10-11" @default.
• W4220756780 title "Abstract P3-03-02: Diffusion-weighted MRI for prediction of pathologic complete response in HER2- breast cancer treated with pembrolizumab plus neoadjuvant chemotherapy" @default.
• W4220756780 doi "https://doi.org/10.1158/1538-7445.sabcs21-p3-03-02" @default.
• W4220756780 hasPublicationYear "2022" @default.
• W4220756780 type Work @default.
• W4220756780 citedByCount "0" @default.
• W4220756780 crossrefType "journal-article" @default.
• W4220756780 hasAuthorship W4220756780A5001969147 @default.
• W4220756780 hasAuthorship W4220756780A5010926549 @default.
• W4220756780 hasAuthorship W4220756780A5012847376 @default.
• W4220756780 hasAuthorship W4220756780A5015982056 @default.
• W4220756780 hasAuthorship W4220756780A5016580708 @default.
• W4220756780 hasAuthorship W4220756780A5023543805 @default.
• W4220756780 hasAuthorship W4220756780A5024284558 @default.
• W4220756780 hasAuthorship W4220756780A5027791567 @default.
• W4220756780 hasAuthorship W4220756780A5033270425 @default.
• W4220756780 hasAuthorship W4220756780A5034796205 @default.
• W4220756780 hasAuthorship W4220756780A5061131007 @default.
• W4220756780 hasAuthorship W4220756780A5072789687 @default.
• W4220756780 hasAuthorship W4220756780A5076174825 @default.
• W4220756780 hasConcept C121608353 @default.
• W4220756780 hasConcept C126322002 @default.
• W4220756780 hasConcept C126838900 @default.
• W4220756780 hasConcept C143409427 @default.
• W4220756780 hasConcept C143998085 @default.
• W4220756780 hasConcept C149550507 @default.
• W4220756780 hasConcept C2776694085 @default.
• W4220756780 hasConcept C2776755627 @default.
• W4220756780 hasConcept C2777111374 @default.
• W4220756780 hasConcept C2777701055 @default.
• W4220756780 hasConcept C2780057760 @default.
• W4220756780 hasConcept C2780472235 @default.
• W4220756780 hasConcept C2781190966 @default.
• W4220756780 hasConcept C2989005 @default.
• W4220756780 hasConcept C530470458 @default.
• W4220756780 hasConcept C58471807 @default.
• W4220756780 hasConcept C70816921 @default.
• W4220756780 hasConcept C71924100 @default.
• W4220756780 hasConcept C72563966 @default.
• W4220756780 hasConcept C76318530 @default.
• W4220756780 hasConceptScore W4220756780C121608353 @default.
• W4220756780 hasConceptScore W4220756780C126322002 @default.
• W4220756780 hasConceptScore W4220756780C126838900 @default.
• W4220756780 hasConceptScore W4220756780C143409427 @default.
• W4220756780 hasConceptScore W4220756780C143998085 @default.
• W4220756780 hasConceptScore W4220756780C149550507 @default.
• W4220756780 hasConceptScore W4220756780C2776694085 @default.
• W4220756780 hasConceptScore W4220756780C2776755627 @default.
• W4220756780 hasConceptScore W4220756780C2777111374 @default.
• W4220756780 hasConceptScore W4220756780C2777701055 @default.
• W4220756780 hasConceptScore W4220756780C2780057760 @default.
• W4220756780 hasConceptScore W4220756780C2780472235 @default.
• W4220756780 hasConceptScore W4220756780C2781190966 @default.
• W4220756780 hasConceptScore W4220756780C2989005 @default.
• W4220756780 hasConceptScore W4220756780C530470458 @default.
• W4220756780 hasConceptScore W4220756780C58471807 @default.
• W4220756780 hasConceptScore W4220756780C70816921 @default.
• W4220756780 hasConceptScore W4220756780C71924100 @default.
• W4220756780 hasConceptScore W4220756780C72563966 @default.
• W4220756780 hasConceptScore W4220756780C76318530 @default.
• W4220756780 hasIssue "4_Supplement" @default.
• W4220756780 hasLocation W42207567801 @default.
• W4220756780 hasOpenAccess W4220756780 @default.
• W4220756780 hasPrimaryLocation W42207567801 @default.
• W4220756780 hasRelatedWork W2081815287 @default.
• W4220756780 hasRelatedWork W2115857576 @default.
• W4220756780 hasRelatedWork W2129685713 @default.
• W4220756780 hasRelatedWork W2139614539 @default.
• W4220756780 hasRelatedWork W2201793188 @default.
• W4220756780 hasRelatedWork W236807388 @default.
• W4220756780 hasRelatedWork W2515537233 @default.
• W4220756780 hasRelatedWork W3095184244 @default.
• W4220756780 hasRelatedWork W3147275309 @default.
• W4220756780 hasRelatedWork W4387023192 @default.
• W4220756780 hasVolume "82" @default.
• W4220756780 isParatext "false" @default.
• W4220756780 isRetracted "false" @default.
• W4220756780 workType "article" @default.